Weekly Market Pulse · Valid through Sunday, August 2, 2026
Weekly Market Pulse
This week is defined by a compressed sequence of market-moving events: the July FOMC decision, Q2 GDP and June PCE inflation data, Big Tech earnings focused on AI capex, and two back-to-back FDA advisory committee meetings for high-risk biotech names.
FOMC July 28-29GDP / PCE July 30$CAPR AdCom July 29$REPL AdCom July 30$REPL PDUFA August 2
Current setup · Published July 29, 2026
The week’s risk is concentrated in policy, inflation, AI spending and FDA decisions
The market enters the final days of July with four overlapping risk clusters. First, the Federal Reserve’s July 28-29 meeting gives the tape a rates catalyst in the middle of the week. Second, the Bureau of Economic Analysis releases the Q2 GDP advance estimate and June Personal Income and Outlays, including PCE inflation, on July 30 at 8:30 a.m. ET. Third, Microsoft and Meta report after the close on July 29, followed by Apple and Amazon on July 30. Fourth, the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee reviews Capricor’s deramiocel BLA on July 29 and Replimune’s RP1 BLA on July 30, with Replimune’s FDA action date expected on August 2.
The practical read-through is straightforward: this is not a quiet summer week. The broad market is watching rates and AI capex; biotech traders are watching FDA tone, panel votes and whether XBI can absorb another high-profile regulatory shock; space, defense and AI infrastructure names are watching whether Big Tech spending remains a tailwind or starts to be treated as a cash-flow burden.
Verified event calendar: July 29-August 2, 2026
| Date | Event | Tickers / sectors | Why it matters this week |
|---|---|---|---|
| July 29 | Federal Reserve FOMC decision and press conference | $SPY, $QQQ, $IWM, $XBI, rates, USD, gold | The official Fed calendar lists the July 28-29 meeting. The market focus is whether policy language, the vote split or the press conference changes expectations for September. |
| July 29 | FDA CTGTAC meeting on Capricor’s deramiocel BLA | $CAPR, DMD, cell therapy, rare disease biotech | The FDA agenda lists BLA 125842 for deramiocel in cardiomyopathy associated with Duchenne muscular dystrophy. FDA staff documents and press coverage have already made this a high-risk regulatory setup. |
| July 29 after close | Microsoft fiscal Q4 2026 results; Meta Q2 2026 results | $MSFT, $META, $QQQ, AI infrastructure | Investors are focused on Azure, AI monetization, capex guidance, free cash flow and whether AI infrastructure spending remains rewarded. |
| July 30, 8:30 a.m. ET | BEA Q2 GDP advance estimate and June Personal Income and Outlays | Rates, $SPY, $IWM, $XBI, cyclicals, gold | The BEA schedule places both GDP and PCE-related data on July 30. The combination can reset the growth/inflation narrative after the Fed decision. |
| July 30 | FDA CTGTAC meeting on Replimune’s RP1 BLA | $REPL, melanoma, oncolytic immunotherapy, $XBI | The FDA agenda lists BLA 125827 for vusolimogene oderparepvec in combination with nivolumab for advanced melanoma after anti-PD-1 therapy. |
| July 30 after close | Apple Q3 FY2026 results and Amazon Q2 2026 results | $AAPL, $AMZN, $QQQ, cloud, consumer, AI capex | Apple and Amazon both have official investor events on July 30 at 2:00 p.m. PT / 5:00 p.m. ET. Amazon also confirms its Q2 2026 call on July 30. |
| August 2 | Replimune RP1 FDA action date | $REPL | Replimune announced FDA acceptance of the BLA resubmission as a complete class 1 response with a goal date of August 2, 2026. |
Market map: what to watch before the weekend
The market is balanced between resilience and event risk. Reuters described a resilient global tape on July 28 despite pressure from Asian tech, oil swings, Fed uncertainty and Big Tech earnings scrutiny. The important question is not only whether indexes rise or fall this week, but which part of the market absorbs the event risk best.
$SPYPolicy and earningsWatch the Fed statement, GDP/PCE and mega-cap earnings reaction.
$QQQAI capex testMicrosoft, Meta, Apple and Amazon decide whether AI spending remains a tailwind.
$IWMRates sensitivitySmall caps need a benign rate reaction and stable breadth.
$XBIFDA stressCapricor and Replimune put regulatory risk directly in focus.
Constructive signs
- A Fed message that does not tighten financial conditions further.
- GDP/PCE data that avoid a stagflationary mix of weaker growth and hotter inflation.
- Big Tech earnings that defend AI capex with visible revenue, cloud demand or margin discipline.
- FDA panels that give clearer paths forward even when the risk remains high.
Risk signals
- A hawkish Fed surprise, more dissents or guidance that pushes rate expectations higher.
- Weak growth data paired with sticky PCE inflation.
- Big Tech capex increases without cash-flow reassurance.
- Negative FDA panel votes or highly restrictive panel language for $CAPR or $REPL.
Biotech catalyst pulse: $CAPR and $REPL dominate the week
Biotech risk is concentrated in two FDA advisory committee meetings. Both are high-stakes, both involve complex clinical/regulatory questions, and both can influence sentiment toward speculative small-cap biotech beyond the individual tickers.
| Ticker | Event | Verified status | Risk interpretation | Hub |
|---|---|---|---|---|
| $CAPR | FDA CTGTAC meeting, July 29 | FDA lists BLA 125842 for deramiocel in DMD cardiomyopathy. Capricor previously stated the advisory committee meeting was scheduled for July 29 and that the BLA remained on track for an August 22, 2026 PDUFA target action date. | Reuters reported that FDA staff raised efficacy and data-analysis concerns ahead of the meeting. This keeps the event in very high-risk territory even before the panel outcome. | Capricor Stock Hub |
| $REPL | FDA CTGTAC meeting, July 30; PDUFA August 2 | FDA lists BLA 125827 for RP1/vusolimogene oderparepvec in combination with nivolumab for advanced melanoma after anti-PD-1 therapy. Replimune announced the FDA action date as August 2, 2026. | Reuters reported FDA staff concerns around benefit, trial design and lack of a control group. The panel and the August 2 action date remain the main near-term biotech binary. | Replimune Stock Hub |
| $XBI | Sector read-through | Two regulatory events inside the same week create a concentrated sentiment test for high-risk biotech. | A constructive outcome could improve risk appetite for catalyst names; negative panel language could keep traders focused on CRLs, financing risk and proof standards. | Biotech Hub |
AI earnings pulse: capex is the number the market wants to believe
The AI trade is entering a more demanding phase. Microsoft and Meta report after the close on July 29. Apple and Amazon follow on July 30. The market is no longer reacting only to revenue beats. Investors are comparing AI infrastructure spending, cloud growth, free cash flow, margins and the credibility of future monetization.
| Ticker | Timing | Main question | Read-through |
|---|---|---|---|
| $MSFT | July 29 after close | Can Azure growth, AI demand and Microsoft 365 Copilot adoption justify the capex curve? | Positive cloud/AI commentary supports AI infrastructure suppliers and the broader $QQQ complex. |
| $META | July 29 after close | Does Meta defend AI spending with advertising strength, compute monetization or better long-term margin visibility? | A larger capex signal without monetization clarity could pressure AI sentiment. |
| $AAPL | July 30 after close | Does Apple show enough product and services resilience while keeping AI spending controlled? | Apple is the cleaner balance-sheet contrast inside mega-cap tech. |
| $AMZN | July 30 after close | Does AWS growth and retail margin resilience offset the scale of AI and logistics investment? | Amazon’s call is important for cloud, consumer demand, data-center capex and power/infrastructure read-throughs. |
Watchlist valid through Sunday, August 2, 2026
This is not a buy list. It is the event map for the remainder of the week.
| Bucket | Tickers | What to watch | Risk level |
|---|---|---|---|
| Broad market | $SPY $QQQ $IWM | FOMC reaction, GDP/PCE data, bond yields, breadth and mega-cap earnings follow-through. | Medium / Macro |
| Biotech tape | $XBI $CAPR $REPL | FDA panel vote, discussion tone, label/confirmatory-trial questions, sell-the-news risk and PDUFA outcome. | Very high / Binary |
| AI mega-cap | $MSFT $META $AAPL $AMZN | Capex, cloud demand, free cash flow, AI monetization and guidance. | High / Earnings |
| AI infrastructure read-through | $POET $BBAI $RDW $PL $ONDS | Whether Big Tech earnings support or weaken the infrastructure-spending narrative. | High / Sentiment |
| Energy and inflation | $XOM oil gold USD | Oil and dollar reaction after the Fed, plus inflation sensitivity after PCE. | Medium / Macro |
Core Merlintrader hubs for the current week
Use the live hubs for company-level detail. This Weekly Pulse is the market map; the hubs are the deeper research base.
Verification sources
The schedule and event references in this weekly pulse are based on primary sources where available and major financial news coverage where primary market interpretation is required.
- Federal Reserve: 2026 FOMC calendar
- Bureau of Economic Analysis: release schedule
- FDA: July 29 CTGTAC meeting, Capricor deramiocel
- FDA: July 30 CTGTAC meeting, Replimune RP1
- Replimune: FDA acceptance of RP1 BLA resubmission and August 2 goal date
- Capricor: July 29 advisory committee and August 22 PDUFA target
- Microsoft: fiscal Q4 2026 earnings timing
- Meta: Q2 2026 earnings timing
- Apple Investor Relations: Q3 FY2026 results call
- Amazon: Q2 2026 results call
Educational disclaimer: This page is for informational and educational purposes only and does not constitute investment advice, financial advice, legal advice, a recommendation or a solicitation to buy or sell any security. Markets, biotech catalysts and small-cap stocks are volatile and can result in partial or total loss of capital. Readers should verify all information with primary sources and consult qualified professionals where appropriate.
Get the next Weekly Pulse in real time
Join the Merlintrader Telegram channel and receive new market recaps, biotech catalyst updates and Stock Hub refreshes as soon as they go live.
Join @merlintrader_eu on Telegram